Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma

Last updated: September 19, 2019
Sponsor: Universiti Kebangsaan Malaysia Medical Centre
Overall Status: Active - Recruiting

Phase

4

Condition

Glaucoma

Open Angle Glaucoma

Treatment

N/A

Clinical Study ID

NCT04098861
FF-2019-058
  • Ages > 18
  • All Genders

Study Summary

Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay progression of glaucoma. IOP reduction has been proven to delay the onset and progression of glaucoma, and uncontrolled IOP is constantly associated with progression of visual field loss.

Medical therapy is the first line in IOP reduction for Primary Open Angle Glaucoma (POAG). It is a known fact that glaucoma patients often require addition of a second antiglaucoma medications when disease progresses or tachyphylaxis occurs. It was reported that more than 50% of patients require 2 or more medications to achieve optimum IOP control.

Nevertheless, compliance and adherence are often impaired with multiple-drug therapy. Combining two ocular hypotensive agents in one bottle may help patients adhere to therapeutic regimen by reducing the number of medications used and the total number of doses administered.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18 and above

  2. Able to provide informed consent

  3. Diagnosed as having unilateral or bilateral, mild to moderate POAG

  4. The POAG treated with only two antiglaucoma

Exclusion

Exclusion Criteria:

  1. Advanced POAG

  2. Patient with contraindication for topical use of a-blocker and prostaglandin analogue

  3. Patient with contraindication for systemic use of a-blocker

  4. Patient on systemic use of a-blocker such as metoprolol, propranolol, atenolol

  5. History of orbital or ocular trauma.

  6. History of cataract surgery less than 6 months.

  7. History of previous ocular surgery; e.g. vitreoretinal surgery, cornealtransplantation or glaucoma surgery

  8. Any active eye infections or corneal ulceration.

  9. Patient with ocular surface disease

  10. Other ocular disease that might interfere with IOP measurements or result

  11. Precious eye i.e patient with only one good eye

  12. Contact lens is not allowed within 1 week before the start of study and during thestudy

Study Design

Total Participants: 40
Study Start date:
January 02, 2019
Estimated Completion Date:
December 01, 2020

Connect with a study center

  • Universiti Kebangsaan Malaysia Medical Centre

    Cheras, Wilayah Persekutuan Kuala Lumpur 56000
    Malaysia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.